In this episode, we hear from our guest: Michelle Longmire, CEO & Co-Founder at Medable.

Topics discussed:

• Michelle Longmire's Inspiration: In medical school, Longmire recognized a critical access gap in healthcare. Training at the University of New Mexico, she observed the challenges faced by underserved patients and envisioned a technological bridge to healthcare.
• Formation of Medable: The idea of Medable was shaped by Longmire's experience at Stanford and the rise of mobile technology. The aim was to create a platform that provided secure, accessible healthcare and research opportunities.
• Early Challenges and Milestones: Winning a pitch contest provided initial funding for Medable. Key hires included experts in platform technology, mobile app development, and enterprise architecture. The first major contract with a pharma company highlighted the need for expanded capabilities.
• Role in Decentralized Clinical Trials: Longmire foresaw mobile technology as a key driver in making research consumer-scale. The focus on patient-centered research and providing better access led to the rise of decentralized clinical trials.
• Vision for Clinical Trial Innovation: Longmire's vision includes leveraging AI and technology to dramatically increase the number of effective therapies tested and approved each year, addressing a wide range of diseases more efficiently.

Michelle Longmire's Social:
LinkedIn: https://www.linkedin.com/in/michellelongmire/

Our sponsor for this episode is H1. H1 is on a mission to create a healthier future by democratizing access to vital healthcare expertise and information globally. They offer comprehensive insights and data, benefiting doctors, researchers, and patients alike. Their innovative solutions are pivotal in accelerating the development and distribution of life-saving treatments and ensuring equitable healthcare access.
Website: https://www.h1.co/
LinkedIn: https://www.linkedin.com/company/h1co/
X: https://twitter.com/H1co_

Towards Health is a part of the Slice of Healthcare podcast network: https://www.linkedin.com/company/sliceofhealthcare/

In this episode, we hear from our guest: Travis Caudill, VP, Feasibility & Clinical Informatics at ICON.

Topics discussed:

• Travis Caudill shares his journey from a health insurance company to becoming an expert in data migration and feasibility in clinical trials.
• The evolution of clinical trial data: Travis emphasizes how the industry has dramatically advanced from manual data entry to leveraging sophisticated AI for better decision-making.
• AI's transformative impact in 2023 and beyond: Travis delves into AI’s role in clinical trials, discussing its benefits and challenges, emphasizing continuous innovation and skepticism in the industry.
• The intersection of AI, diversity, and site selection: Travis highlights the critical importance of aligning AI-driven technology with patient needs, emphasizing the need for inclusivity and efficient site selection in clinical trials.

Travis Caudill's Social:
LinkedIn: https://www.linkedin.com/in/feasibility/

Our sponsor for this episode is H1. H1 is on a mission to create a healthier future by democratizing access to vital healthcare expertise and information globally. They offer comprehensive insights and data, benefiting doctors, researchers, and patients alike. Their innovative solutions are pivotal in accelerating the development and distribution of life-saving treatments and ensuring equitable healthcare access.
Website: https://www.h1.co/
LinkedIn: https://www.linkedin.com/company/h1co/
X: https://twitter.com/H1co_

Towards Health is a part of the Slice of Healthcare podcast network: https://www.linkedin.com/company/sliceofhealthcare/

In this episode, guests Craig Lipset, Founder at Clinical Innovation Partners, and Angela Radcliffe, Founder at How We Mighty Ventures, discuss AI's transformative role in clinical trials.

Topics discsued:

• The potential and challenges of AI in healthcare.

• Strategies for integrating AI in clinical trial processes.

• The balance between technological innovation and patient-centric approaches.

• Expert Insights: In-depth analysis from leaders in the healthcare and technology sectors.

• Reflecting on the key takeaways about the future impact of AI in clinical trials.

Craig Lipset's Social:
LinkedIn: https://www.linkedin.com/in/lipset/

Angela Radcliffe's Social:
LinkedIn: https://www.linkedin.com/in/angela-radcliffe-2560256/

Our sponsor for this episode is H1. H1 is on a mission to create a healthier future by democratizing access to vital healthcare expertise and information globally. They offer comprehensive insights and data, benefiting doctors, researchers, and patients alike. Their innovative solutions are pivotal in accelerating the development and distribution of life-saving treatments and ensuring equitable healthcare access.
Website: https://www.h1.co/
LinkedIn: https://www.linkedin.com/company/h1co/
X: https://twitter.com/H1co_

Towards Health is a part of the Slice of Healthcare podcast network: https://www.linkedin.com/company/sliceofhealthcare/

In this episode, Omar Khateeb, Founder at Khateeb & Co joins to discuss a MedTech year in review.

Listen to discover: 

• Khateeb's background. 
• The three greatest industry or regulatory influences on the medical device or med tech industry this year
• How he thinks data and innovation have changed how med tech sales teams function
• How hospital financials are impacting med tech
• How clinician or clinical worker burnout has affected med tech efforts
• The three best skills a med device rep can develop in the next year to succeed through a potential recession
• Khateeb's number one prediction for the med tech industry in 2023

Sponsored by: H1 (https://www.h1.co/)

To learn more about Khateeb & Co please use the links below:

- LinkedIn - Omar's LinkedIn

Also, be sure to follow Slice of Healthcare on our social channels:

- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter

In this episode Anthony Harries, Honorary Professor at the London School of Hygiene & Tropical Medicine, and Gavin Koh Global Product Lead at AstraZeneca join to discuss their Faculty Opinions perspective on the question "Is Peer Reviewed Research the Answer to Preventing Another Global Health Crisis?". 

Episode Context: 

When the pandemic hit and there was a global effort to quickly and effectively develop a COVID-19 vaccine, there was a lot of misinformation shared that lacked scientific merit. There was also a lot of research to go through. How could physicians and researchers discern what to read and focus on? Today’s discussion is with faculty from Faculty Opinions sharing why peer-reviewed research is not only important but critical to the future of another global health crisis.

To learn more about Anthony Harries & Gavin Koh please use the links below:
- Harries' LinkedIn - Koh's LinkedIn

To learn more about Faculty Opinions please use the links below:
- Website - LinkedIn

Sponsored by: H1 (https://www.h1.co/)

To learn more about H1 please use the links below:

- Website - LinkedIn

Also, be sure to follow Slice of Healthcare on our social channels:

- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter

In this episode, Chris Madeiros, Director of Strategy & Solutions at H1 and Nayanica Banerjee, Senior Manager of Client Solutions & Strategy at H1 join to discuss the intersection of KOLs and DOLs while talking about research and medical affairs. 

Listen to discover: 

• Madeiros & Banerjee's backgrounds in the industry
• What the term digital opinion leader mean to them, how that has changed over time
• If they believe DOLs have the same credibility as traditional KOLs
• Looking into the future - do you think we will have congresses and printed publications of research in 10 years?

Keep an eye out for part 2 on this topic coming soon! 

Sponsored by: H1 (https://www.h1.co/)

To learn more about H1 please use the links below:

- Website - LinkedIn

Also, be sure to follow Slice of Healthcare on our social channels:

- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter

In this episode Brad Hightower, CEO at Hightower Clinical, and Darshan Kulkarni, Regulatory and Compliance Attorney for the Life Sciences at The Kulkarni Law Firm join to discuss the 2022 Pharma Year in Review.  

Listen to discover: 

• The biggest A-Ha moments and challenges for Pharma this year
• How they see the economic downturn having an impact on the industry
• Where data or technology innovation had the greatest impact on clinical trials and/or drug developments
• Whether FDA guidelines will be a motivator or a hindrance on things like trial diversity next year
• How they see social media channels and digital opinion leaders or influencers' impact on scientific communication and exchange evolving next year
• What they are most excited about for 2023 when it comes to innovation, trials or new developments in drug therapies

To learn more about Hightower Clinical please use the links below:
- Website - LinkedIn

To learn more about The Kulkarni Law Firm please use the links below:
- Website - LinkedIn

Be sure to also check out our guests' own podcasts:
Note to File, hosted by Brad Hightower

Darshan Talks, hosted by Darshan Kulkarni

Sponsored by: H1 (https://www.h1.co/)

To learn more about H1 please use the links below:

- Website - LinkedIn

Also, be sure to follow Slice of Healthcare on our social channels:

- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter

In this episode Meredith Dees, VP of Product at Lokavant & Todd Johnson, VP of Customer Success at Lokavant join to talk about big data, health equity, & the future of clinical trials. 

Listen to discover: 

• The effect that time & costs have on clinical trials, and how data & analytics can impact these factors for the better
• Why it is critical to have a connected & consistent source of data for optimized trials to avoid disparities when gathering large amounts of data
• Lokavant's recent partnership with H1 and why that felt like an important partnership
• The role of innovation like AI in accelerating the quality and timeliness of trials
• How data/analytics can amplify the efforts of decentralized trials, which are being called the future of bringing medicines to market faster and in a more equitable way. 

To learn more about Lokavant please use the links below:
- Website - LinkedIn

Sponsored by: H1 (https://www.h1.co/)

To learn more about H1 please use the links below:

- Website - LinkedIn

Also, be sure to follow Slice of Healthcare on our social channels:

- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter

In this episode Jocelyn Levin, Senior Customer Success Manager at H1 joins to discuss her thoughts on customer support & success for Pharma and Life Science companies

Listen to discover: 

• Levin's background & journey at H1
• How Levin defines customer success & how this translates through different environments such as B2B, health tech, and health start-ups
• One of the biggest challenges her clients face when utilizing life science data platforms
• What Levin considers the differences between customer success, experience, and support
• Why customer success is important and why it's important to share the successes with a broader market
• Why is a defined strategy & collaboration important to building a CS team

Sponsored by: H1 (https://www.h1.co/)

To learn more about H1 please use the links below:

- Website - LinkedIn

Also, be sure to follow Slice of Healthcare on our social channels:

- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter

In this episode Stacey Rivkin, Vice President of Client Solutions & Strategy at H1 joins to discuss Uncut GEMS: how treatment leaders with revolutionize Pharma and where to find them.

Listen to discover: 

• Rivkin's background in the industry
• Some of the changes she's seen in the pharma, biotech and life sciences industry in the last couple years
• An overview of the different types of key opinion leaders (KOLs) that Medical Affairs teams and Medical Science Liaisons seek out and interact with
• The term Uncut GEMs - what this means, who these people are, and why this segment of KOLs is considered untapped
• How the term KOL can encompass a lot of different providers, and how this is important to diversify the pool of thought leaders that Pharma engages with

Sponsored by: H1 (https://www.h1.co/)

To learn more about H1 please use the links below:

- Website - LinkedIn

Also, be sure to follow Slice of Healthcare on our social channels:

- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter